ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Gilead Opens Access To HIV Treatments

by Lisa M. Jarvis
July 18, 2011 | APPEARED IN VOLUME 89, ISSUE 29

Gilead Sciences has expanded access to its HIV medicines through agreements with the Medicines Patent Pool Foundation (MPPF), a nonprofit supported by UNITAIDand the Indian drug firms Hetero Drugs, Matrix Laboratories, Ranbaxy Laboratories, and Strides Arcolab. Both MPPF and the companies gain the right to produce for the developing world three drugs in late-stage clinical trials: elvitegravir, an integrase inhibitor; cobicistat, an antiretroviral boosting agent; and the Quad, which combines four Gilead HIV medicines in a once-daily pill. In 2006, Gilead allowed several manufacturers to make generic versions of the HIV drugs Viread and Truvada.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment